CE mark approval for Silicone PHMB Foam Dressing

RNS Number : 9471F
Advanced Medical Solutions Grp PLC
20 November 2020

20 November 2020

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)


            CE mark approval for Silicone PHMB Foam Dressing


~ New product approval in Europe further strengthens AMS’s global advanced woundcare range ~


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that it has received CE mark approval for the Group’s Silicone PHMB Foam Dressing, which sits alongside the US approval for this product (announced in July 2019). The product will be commercialised via AMS’s network of woundcare partners and distributors in CE mark approved markets.


The PHMB Foam Dressing is a polyurethane foam impregnated with Polyhexamethylene Biguanide along with an atraumatic perforated silicone wound contact layer. The dressing is indicated for use in the management of various wounds including pressure sores, diabetic ulcers, post-op surgical wounds and burns. The product can manage wound exudate as well as microbial contamination and the atraumatic silicone layer reduces wound pain during wound healing and dressing changes. The PHMB Foam Dressing has been shown to be highly effective against MRSA and a broad spectrum of microbes, with in vitro testing demonstrating total eradication of MRSA, MRSE, and E. coli within 24 hours, compared to market-leading silver products which failed to achieve this within seven days.


Chris Meredith, Chief Executive Officer of Advanced Medical Solutions, said: “This new product approval in Europe for Silicone PHMB Foam Dressing further strengthens AMS’s advanced woundcare portfolio in Europe and reinforces the fact that our R&D and Regulatory capabilities are a key pillar of our organic growth strategy.”


-End –


For further information, please contact:


Advanced Medical Solutions Group plc

  Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser


Investec Bank plc (NOMAD & Broker)

Daniel Adams / Patrick Robb / Gary Clarence



Tel: 44 (0) 20 7597 5970



About Advanced Medical Solutions Group plc


AMS is a world-leading developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.